États-Unis - anglais - NLM (National Library of Medicine)

tya pharmaceuticals - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [usp'u] in 1 ml - important: do not change the type of insulin you use unless told to do so by your healthcare provider. the amount of insulin you take as well as the best time for you to take your insulin may need to change if you take a different type of insulin. know your insulin. make sure that you know the type and strength of insulin that is prescribed for you. read the patient information leaflet that comes with novolin 70/30 before you start taking it and each time you get a refill. there may be new information. this leaflet does not take the place of talking with your healthcare provider about your diabetes or your treatment. make sure you know how to manage your diabetes. ask your healthcare provider if you have any questions about managing your diabetes. ® what is novolin 70/30? ® novolin 70/30 is a man-made insulin (recombinant dna origin) which is a mixture of 70% nph, human insulin isophane suspension and 30% regular, human in

États-Unis - anglais - NLM (National Library of Medicine)

a-s medication solutions - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [iu] in 1 ml - novolin n is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. novolin n is contraindicated: risk summary available data from published studies over decades have not established an association with human insulin use during pregnancy and major birth defects, miscarriage or adverse maternal or fetal outcomes (see data). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). animal reproduction studies were not performed. the estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a hba1c >7 and has been reported to be as high as 20-25% in women with a hba1c >10. the estimated background risk of miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. clinical considerations diseas

États-Unis - anglais - NLM (National Library of Medicine)

a-s medication solutions - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [usp'u] in 1 ml - novolin 70/30 is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. limitations of use: in novolin 70/30, the proportions of short-acting and intermediate-acting insulins are fixed and do not allow for basal versus prandial dose adjustments. novolin 70/30 is contraindicated: risk summary available data from published studies over decades have not established an association with human insulin use during pregnancy and major birth defects, miscarriage or adverse maternal or fetal outcomes (see data). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). animal reproduction studies were not performed. the estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a hba1c >7 and has been reported to be as high as 20-25% in women with a hba1c >10. the estimated background risk of miscarriage for the indicated population is unknown. in the u.s. general

États-Unis - anglais - NLM (National Library of Medicine)

a-s medication solutions - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [iu] in 1 ml - novolin r is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. novolin r is contraindicated: risk summary available data from published studies over decades have not established an association with human insulin use during pregnancy and major birth defects, miscarriage or adverse maternal or fetal outcomes (see data). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). animal reproduction studies were not performed. the estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a hba1c >7 and has been reported to be as high as 20-25% in women with a hba1c >10. the estimated background risk of miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. clinical considerations diseas

États-Unis - anglais - NLM (National Library of Medicine)

boehringer ingelheim animal health usa inc. - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 40 [iu] in 1 ml - prozinc is contraindicated in cats sensitive to protamine zinc recombinant human insulin or any other ingredients in prozinc. prozinc is contraindicated during episodes of hypoglycemia. prozinc is contraindicated in dogs sensitive to protamine zinc recombinant human insulin or any other ingredients in prozinc. prozinc is contraindicated during episodes of hypoglycemia.

Israël - anglais - Ministry of Health

eli lilly israel ltd, israel - insulin (human) - solution for injection - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis

Israël - anglais - Ministry of Health

eli lilly israel ltd, israel - insulin (human) - solution for injection - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis

Israël - anglais - Ministry of Health

eli lilly israel ltd, israel - insulin (human) - suspension for injection - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis

Israël - anglais - Ministry of Health

eli lilly israel ltd, israel - insulin (human) - suspension for injection - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis

Israël - anglais - Ministry of Health

eli lilly israel ltd, israel - insulin (human) - suspension for injection - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis